LCTX
Lineage Cell Therapeutics, Inc. · Healthcare · Market cap $195.2M
Insiders bought $871K net in the last 90 days ·0 sellers, 5 buyers· latest Form 4 filed Nov 19, 2026
Insider Buying
$895K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Nov 19, 2026
Mulroy Michael H.
Lineage Cell Therapeutics, Inc. (LCTX) has 10 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Nov 19, 2026.
Inside the rolling window, 5 insiders at Lineage Cell Therapeutics, Inc. reported 6 open-market purchases totaling $895K and no open-market sales. Insiders have net bought $871K over the trailing 6 months. The most recent open-market filing is a purchase of 30,000 shares by Director Mulroy Michael H., dated Nov 17, 2026, worth $26K.
- Industry:Biotechnology
- CEO:Brian Culley
- Employees:75
- HQ:Carlsbad, CA, US
- IPO:1992-03-05
| Source | |||||||
|---|---|---|---|---|---|---|---|
Mulroy Michael H.First filing | Director | Purchase | 30,000 | $26K | Nov 19 | cluster-5.9% | SEC ↗ |
BROADWOOD PARTNERS, L.P.First in 7 months | Director, 10% Owner | Purchase | 1,000,000 | $771K | Nov 19 | cluster-5.9% | SEC ↗ |
Culley Brian MFirst in 8 months | President and CEO | Purchase | 40,500 | $37K | Nov 17 | cluster-5.9% | SEC ↗ |
ANDREWS DEBORAH JFirst filing | Director | Purchase | 25,000 | $20K | Nov 17 | cluster-5.9% | SEC ↗ |
Howe Jill AnnFirst filing | Chief Financial Officer | Purchase | 20,000 | $17K | Nov 16 | cluster-3.5% | SEC ↗ |
Culley Brian MFirst filing | President and CEO | Purchase | 15,000 | $24K | Mar 12 | -51.1% | SEC ↗ |
Earnings: last 7 quarters
Congress trading LCTX 1 all-time
- RRep. Anna LunaSale$1,001 - $15,0002024-01-02
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does LCTX have?
Lineage Cell Therapeutics, Inc. (LCTX) has 10 SEC Form 4 filings (14 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Nov 19, 2026.
When was the most recent SEC Form 4 filing for LCTX?
The most recent Form 4 filing for LCTX on Tracefour is dated Nov 19, 2026.
What is the net insider flow at LCTX over the last 6 months?
Over the trailing 180 days, insiders at LCTX have net bought $871K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at LCTX in the current window?
Inside the rolling window, insiders at LCTX bought $895K and sold $0 based on SEC Form 4 filings.
Can I get alerts for LCTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Lineage Cell Therapeutics, Inc. (LCTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Lineage Cell Therapeutics, Inc. is in the Healthcare sector.